Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Industry (Medical Devices)

Industry (Medical Devices)

                        Letters to Industry
          Send and Track Medical Device Premarket Submissions Online: CDRH Portal Home
          Medical Devices
          Resources for You (Medical Devices)
          Industry (Medical Devices)
          Letters to IndustryIndustry (Medical Devices) Letters to Industry
  
  	
    Share
    Post
    Linkedin

    Email
    PrintThis webpage is a resource for external stakeholders that contain correspondence issued by the Center for Devices and Radiological Health (CDRH) for a variety of purposes. These primarily include Warning Letters, Untitled Letters, "It Has Come To Our Attention" letters and letters used to communicate broadly with industry.

Chapter 4 of the Regulatory Procedures Manual (RPM) contains Agency guidance and procedures for Warning Letters and Untitled Letters.

Warning Letters

Chapter 4-1-1 of the RPM, on Warning Letter Procedures states "When it is consistent with the public protection responsibilities of the agency and depending on the nature of the violation, it is the Food and Drug Administration's (FDA) practice to give individuals and firms an opportunity to take voluntary and prompt corrective action before it initiates an enforcement action. Warning Letters are issued to achieve voluntary compliance and to establish prior notice. (Prior notice is discussed in Chapter 10 of the Regulatory Procedures Manual. The use of Warning Letters and the prior notice policy are based on the expectation that most individuals and firms will voluntarily comply with the law.

The agency position is that Warning Letters are issued only for violations of regulatory significance. Significant violations are those violations that may lead to enforcement action if not promptly and adequately corrected. A Warning Letter is the agency's principal means of achieving prompt voluntary compliance with the Federal Food, Drug, and Cosmetic Act (the Act)."

Consistent with Chapter 4-1-13 of the RPM on Freedom of Information, all FDA-issued Warning Letters (redacted) should be posted on FDA.gov to permit the public to obtain a copy directly without the need to submit a formal FOIA request.

View all Warning Letters, including those issued by CDRH, at FDA's main page for Warning LettersUntitled Letters

Chapter 4-2-1 of the RPM, Untitled Letters Policy states "An Untitled Letter cites violations that do not meet the threshold of regulatory significance for a Warning Letter." Unlike a Warning Letter, an Untitled Letter does not include a statement that warns the individual or firm that failure to promptly correct the violation may result in enforcement action.

Consistent with Agency practice described on the Issuance of Untitled Letters webpage, webpage, FDA generally posts an Untitled Letter to a Center website on FDA.gov when the Center has determined posting would be appropriate because one or more of the following apply: (1) FDA has received or anticipates receiving 3 or more requests for the letter under the Freedom of Information Act (FOIA); (2) FDA believes that doing so would inform the public about violative practices and conditions that may pose a risk to their health; (3) FDA believes that doing so would deter future violations and allow similarly situated regulated entities to determine what activities and practices FDA finds violative and use the information to increase compliance with the law. This policy does not preclude Center offices from electing to proactively post all untitled letters within a particular program area. Where FDA adopts an approach to posting untitled letters in a particular program area, the posting will be done as soon as possible, but normally no later than 10 workdays after the letter has been issued.

It Has Come to Our Attention Letters (IHCTOA)

In certain situations, CDRH may become aware that regulated industry *may* be promoting a medical device product in a manner that potentially violates the Federal Food, Drug, and Cosmetic Act and its implementing regulations. CDRH may issue an "It Has Come to Our Attention" Letter (IHCTOA Letter) to regulated industry as an early communication to gather additional information and provide the member of regulated industry. Certain IHCTOA letters were publicly posted prior to the update of this website, and remain available here. These letters are not intended to communicate that FDA is considering enforcement action and therefore will not be publicly posted in the future, but remain subject to disclosure pursuant to FOIA.

Communication Letters

CDRH also issues letters to industry, which are intended to serve as communication products that inform industry broadly of issues related to specific devices or a class of devices. CDRH generally posts these letters to ensure widest distribution of messaging.

Letters to Industry (Medical Devices)

Title
			Category
			DateTransition to Electronic Export Documents - Letter to Industry
			Communication
			01/02/24Electronic Export Documents – Letter to Industry
			Communication
			07/10/23Studies Using Leftover, Deidentified Human Specimens Require IRB Review – Letter to Industry
			Communication
			10/18/21Potential Postmarket Safety Issue Regarding the Use of ENFit Low Dose Tip (LDT) Syringes and Concerns with Dose Accuracy
			Communication
			10/08/21Use Purple Bracelets or Wristbands Only for Do Not Resuscitate Status - August 16, 2021
			Communication
			08/16/21Notification of Defect Letter to Max-Lux Corporation Limited - June 17, 2021
			Communication
			06/17/21Sterility Issues with Medical Devices Processed at Steril Milano Facilities - June 2, 2021
			Communication
			06/02/21Letter to Industry on COVID-19 - March 23, 2020
			Communication
			03/23/20Labeling Request Letter to Pen Needle Manufacturers - September 27, 2018
			Communication
			09/27/18Letter to Manufacturers of Enteral Feeding Tubes, Health Care Professionals, and Hospital Purchasing Departments and Distributors: The FDA Encourages Use of Enteral Device Connectors that Reduce Risk of Misconnection and Patient Injury - September 7, 2018
			Communication
			09/07/18UDI Extension Letter to Manufacturers of Drug/Device or Biologic/Device Combination Products assigned to Center for Drug Evaluation and Research (CDER) for Premarket Review - August 9, 2018 (PDF - 86KB)
			Communication
			08/09/18Venus Concept, Ltd. - August 1, 2018 (PDF - 37KB)
			IHCTOA
			08/01/18BTL Industries, Inc. Letter - July 26, 2018 (PDF - 37KB)
			IHCTOA
			07/26/18Cynosure, Inc. Letter - July 24, 2018 (PDF - 42KB)
			IHCTOA
			07/24/18Alma Lasers Letter - July 24, 2018 (PDF - 40KB)
			IHCTOA
			07/24/18Sciton, Inc. Letter - July 24, 2018 (PDF - 37KB)
			IHCTOA
			07/24/18Thermigen, Inc. Letter - July 24, 2018 (PDF - 37KB)
			IHCTOA
			07/24/18Inmode MD Ltd. Letter - July 24, 2018 (PDF - 57KB)
			IHCTOA
			07/24/18Letter to Hearing Aid Manufacturers about Over-the-Counter (OTC) Hearing Aids - July 24, 2018 (PDF - 67KB)
			Communication
			07/24/18Letter to Device Labelers on UDI Compliance Dates for Class I and Unclassified Devices – June 2, 2017 (PDF - 80KB)
			Communication
			06/02/17UDI Extension Letter to Soft Contact Lens Labelers - March 30, 2017 (PDF - 66KB)
			Communication
			03/30/17Letter to Viracor-IBT Laboratories, Inc. regarding Zika Virus IgG, and Zika Virus IgG and IgM Panel (PDF - 921KB)
			IHCTOA
			10/21/16UDI Extension Letter to Device Labelers - September 6, 2016 (PDF - 163KB)
			Communication
			10/06/16UDI Extension Letter to Rigid Gas Permeable Contact Lens Manufacturers - September 22, 2016 (PDF - 128KB)
			Communication
			09/22/16Syringe Pump Labeling Request Letter (PDF - 69KB)
			Communication
			08/24/16Soft Tissue Fillers Labeling Request Letter (PDF - 38KB)
			Communication
			05/26/16Letter to Medical Diagnostic Laboratories, LLC regarding the Zika Virus–Blood–PCR Test (PDF - 40KB)
			IHCTOA
			03/23/16Letter to First Diagnostic Corporation regarding the ATFirst’s One Step Zika Antibody Test (PDF - 691KB)
			IHCTOA
			03/10/16Letter to MD Biosciences Regarding the Zika Virus RNA by RT-PCR Assay (PDF - 357KB)
			IHCTOA
			03/04/16Letter to Texas Children’s Hospital and Houston Methodist Hospital regarding the Zika Direct Test (PDF - 558KB)
			IHCTOA
			03/02/16Letter to Sure Genomics, Inc. concerning SureDNA Test for Collection of Saliva Samples for DNA Sequencing (PDF - 122KB)
			IHCTOA
			02/16/16Letter to SoloPAP concerning the SoloPAP Home HPV&PAP test (PDF - 202KB)
			IHCTOA
			02/07/16Hoya (Pentax) Corp 510k Status Letter - August 12, 2015 (PDF - 449KB)
			IHCTOA
			08/12/15Letter to Endometrial Ablation Industry about Objective Performance Criteria (PDF - 97KB)
			IHCTOA
			08/12/15Pathway Genomics Letter - September 21, 2015 (PDF - 48KB)
			IHCTOA
			09/21/15DuPont Letter Regarding Transition Tyvek (PDF - 199KB)
			Communication
			10/29/15Fujifilm Corp 510k Status Letter - August 12, 2015 (PDF - 604KB)
			Communication
			10/02/15Letter to Kailos Genetics, Inc. concerning test to analyze multiples genes (PDF - 176KB)
			IHCTOA
			11/16/15Letter to Harmonyx concerning test for antiplatelets, statins, ADHD, and pain (PDF - 174KB)
			IHCTOA
			11/16/15Letter to Interleukin Genetics, Inc. Concerning the PerioPredict® Genetic Test (PDF - 211KB)
			IHCTOA
			11/04/15Letter to DNA-Cardiocheck, Inc. Concerning the DNA CardioCheck Test (PDF - 167KB)
			IHCTOA
			11/02/15Letter to DNA4Life Concerning the Pharmacogenetic Report (PDF - 164KB)
			IHCTOA
			11/02/15Letter to Healthspek LLC concerning the Healthspek PGT test for genes affecting drug metabolism (PDF - 161KB)
			IHCTOA
			12/07/15Letter to Genomic Express, Inc. concerning pharmacogenomic tests (PDF - 185KB)
			IHCTOA
			12/07/15UDI Extension Letter to Implant Labelers - November 19, 2014 (PDF - 119KB)
			Communication
			11/19/14UDI Extension Letter to Class III Contact Lens and Intraocular Lens Labelers - August 15, 2014
			Communication
			08/19/14Olympus Medical Systems It Has Come To Our Attention Letter - March 18, 2014 (PDF - 391KB)
			IHCTOA
			03/18/14Letter Regarding Removal of Notary Block on Export Certificates
			Communication
			03/01/14Letter to Medical Device Establishments: Enhancements to CDRH Export Certification and Tracking System (CECATS) (PDF - 86KB)
			Communication
			02/24/14Letter to Biosense Technologies Private Limited concerning the uChek Urine Analyzer
			IHCTOA
			05/21/13Letter to Manufacturers Concerning SIDS Prevention Medical Claims for Baby Products
			Communication
			10/17/11Letter To Foreign and Domestic Medical Device and Component Establishments That May Be Affected by the March 2011 Japan Earthquake and Tsunami
			Communication
			06/01/11Letter to Lumigenix Inc Concerning Direct to Consumer Advertising
			IHCTOA
			05/11/11Letter to American International Biotechnology Services Concerning Direct to Consumer Advertising
			IHCTOA
			05/11/11Letter to Precision Quality DNA Concerning Direct to Consumer Advertising
			IHCTOA
			05/11/11Correspondence related to Duke University Prospective Study Evaluating the Role of Pemetrexed Plus Gemcitabine Chemotherapy for Chemo-naïve Select Stage IIB and IV Non-Small Cell Lung Cancer (NSCLC) in Patients Using a Genome Predictor of Platinum-Resistance to Guide Therapy
			Communication
			03/01/11Letter to Manufacturers of Troponin Assays Listed with the FDA
			Communication
			12/01/10Letter to Manufacturers of Blood Glucose Monitoring Systems Listed With the FDA
			Communication
			12/01/10Letter to IDENTIGENE Concerning the Identigene STD Test
			IHCTOA
			11/04/10Letter to Manufacturers Concerning Medical Claims About Infant Sleep Positioners: Devices Can Create Risk of Suffocation
			Communication
			09/29/10Letter to Manufacturers of 510(k)-cleared Infant Positioners: Devices Can Create Risk of Suffocation
			Communication
			09/29/10Letters to Manufacturers Concerning Genetic Tests
			IHCTOA
			07/19/10Letter to Manufacturers With HbA1c Assays Listed With the FDA
			Communication
			06/10/10Letter to Navigenics Concerning the NaviGenics Health Compass (PDF - 114KB)
			Communication
			06/10/10Letter to Illumina, Inc. Concerning the Illumina Infinium HumanHap550 array (PDF - 169KB)
			Communication
			06/10/10Letter to 23andMe, Inc. Concerning the 23andMe Personal Genome Service (PDF - 163KB)
			Communication
			06/10/10FDA Letter to Firms with Marketing Clearance for No-rub Multipurpose Contact Lens Solutions
			Communication
			05/29/09

                                                                                  Content current as of:
      01/02/2024
              
              
Regulated Product(s)
		 Medical DevicesIndustry (Medical Devices)

          
                        Letters to Industry
          Send and Track Medical Device Premarket Submissions Online: CDRH Portal
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop